fashion -WSS

fashion

author：comprehensive 2025-10-02 00:52:02 - browse：97

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Canadians with cystic fibrosis outlive Americans by a decade

entertainment

WSS

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Undocumented workers face uncertainty as immigration law takes effect in Florida

Dexcom's push to bring CGM to type 2 diabetes patients

Skip the lead apron during X

Congressmen charge Covid hearing ‘could have been an email’

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medical records are filled with copy

Prescription digital therapeutics are key to pharma’s future

Jerome Adams on the need for new antivirals for Covid

A letter from the executive editor: The 2023 STATUS List

The high cost of giving birth even with insurance

Undocumented workers face uncertainty as immigration law takes effect in Florida

Cancer drug shortages should be causing more outrage

A letter from the executive editor: The 2023 STATUS List

Apple is now the first public company to be valued at $3 trillion

Vertex cell therapy lets patients with type 1 diabetes stop insulin

knowledge

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Dexcom's push to bring CGM to type 2 diabetes patients

Even great ERs can’t make up for American health disparities

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

A letter from the executive editor: The 2023 STATUS List

STAT wants to know your pick for a great summer read or listen

hotspot

entertainment

explore

hotspot